“Insmed is going further in our mission by expanding our reach to help significantly more patients across our three therapeutic areas. I feel privileged to work with colleagues who are passionate and committed to bringing ARIKAYCE and BRINSUPRI to patients while advancing our development programs and continuing to progress groundbreaking science in pursuit of new first- and best-in-class therapies. 2026 promises to be another exciting year.”